Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125941191 | 12594119 | 1 | I | 20160529 | 20160712 | 20160726 | 20160726 | EXP | IT-AUROBINDO-AUR-APL-2016-09265 | AUROBINDO | 19.70 | YR | F | Y | 0.00000 | 20160726 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125941191 | 12594119 | 1 | PS | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 280 MG, TOTAL | 77031 | 280 | MG | ||||||||
| 125941191 | 12594119 | 2 | SS | TAVOR (LORAZEPAM) | LORAZEPAM | 1 | Oral | 20 DF, TOTAL | 0 | 20 | DF | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125941191 | 12594119 | 1 | Product used for unknown indication |
| 125941191 | 12594119 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125941191 | 12594119 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125941191 | 12594119 | Drug abuse | |
| 125941191 | 12594119 | Sopor | |
| 125941191 | 12594119 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125941191 | 12594119 | 1 | 20160529 | 20160529 | 0 | |
| 125941191 | 12594119 | 2 | 20160529 | 20160529 | 0 |